1
|
Bui ATN, Son H, Park S, Oh S, Kim JS, Cho JH, Hwang HJ, Kim JH, Yi GS, Chi SW. Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor. Biochem Biophys Res Commun 2021; 588:97-103. [PMID: 34953212 DOI: 10.1016/j.bbrc.2021.12.061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 12/16/2021] [Indexed: 11/18/2022]
Abstract
Apoptosis plays an essential role in maintaining cellular homeostasis and preventing cancer progression. Bcl-xL, an anti-apoptotic protein, is an important modulator of the mitochondrial apoptosis pathway and is a promising target for anticancer therapy. In this study, we identified octenidine as a novel Bcl-xL inhibitor through structural feature-based deep learning and molecular docking from a library of approved drugs. The NMR experiments demonstrated that octenidine binds to the Bcl-2 homology 3 (BH3) domain-binding hydrophobic region that consists of the BH1, BH2, and BH3 domains in Bcl-xL. A structural model of the Bcl-xL/octenidine complex revealed that octenidine binds to Bcl-xL in a similar manner to that of the well-known Bcl-2 family protein antagonist ABT-737. Using the NanoBiT protein-protein interaction system, we confirmed that the interaction between Bcl-xL and Bak-BH3 domains within cells was inhibited by octenidine. Furthermore, octenidine inhibited the proliferation of MCF-7 breast and H1299 lung cancer cells by promoting apoptosis. Taken together, our results shed light on a novel mechanism in which octenidine directly targets anti-apoptotic Bcl-xL to trigger mitochondrial apoptosis in cancer cells.
Collapse
Affiliation(s)
- Anh Thi Ngoc Bui
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea
| | - Hyojin Son
- Department of Bio and Brain Engineering, KAIST, Daejeon, 34141, Republic of Korea
| | - Seulki Park
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea
| | - Sohee Oh
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea
| | - Jin-Sik Kim
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea
| | - Jin Hwa Cho
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea
| | - Hye-Jin Hwang
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea; Department of Proteome Structural Biology, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, 34113, Republic of Korea
| | - Jeong-Hoon Kim
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea; Department of Bioscience, University of Science and Technology, Daejeon, 34113, Republic of Korea; Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea.
| | - Gwan-Su Yi
- Department of Bio and Brain Engineering, KAIST, Daejeon, 34141, Republic of Korea.
| | - Seung-Wook Chi
- Disease Target Structure Research Center, KRIBB, Daejeon, 31441, Republic of Korea; Department of Proteome Structural Biology, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon, 34113, Republic of Korea.
| |
Collapse
|